AlcHepNet ITAALD Trial | Multi-center clinical study advancing research in severe alcohol-associated hepatitis | Collaborative. Innovative. Patient-focused.
The ITAALD trial is now enrolling patients with sAH.
This multicenter, randomized study evaluates IL-22 (F-652) vs prednisone + integrated AUD therapy (acamprosate + counseling) to improve liver & alcohol-related outcomes.
Learn more https://t.co/URvAxe80S2
New publication out in JHEP Reports from @Bernd_Schnabl and team! 🎉
Peptide YY reduces Candida albicans cytotoxicity in alcohol-associated liver disease—opening new directions for microbiome-targeted therapies. 🔗 https://t.co/0g09PRLkfK
@AlcHepNet work in @JAMANetworkOpen led by @LaurenNephewMD@nagachalasani
Only 37% of AH pts referred for transplant
Neighborhood disadvantage shapes referral - we’re missing pts before they even reach transplant. Referral is key equity leverage point
https://t.co/r5icpTpCJu
Excited to share that the ITAALD trial has been officially launched!
This trial is investigating IL-22 followed by AUD tx in severe alcohol-associated hepatitis, building on promising phase 2 results:
https://t.co/K7PKo53PsK
@AlcHepNet@NIAAAnews@Dr_Vijay_Shah@juanpabloarab
ITAALD Study now OPEN for enrollment!
We’re enrolling sAH patients (MELD 20–35). If you have patients who may qualify, we’d love to connect.
Active sites: IU, VCU, UTSW, Cleveland Clinic, Mayo Clinic, University of Louisville.
For more details:
https://t.co/YNOYNALm35
New publication 🚨
“Neighborhood Disadvantage and Access to Liver Transplant Referral for Severe Alcohol-Associated Hepatitis” by @LaurenNephewMD highlights disparities in transplant referral access.
#HealthEquity#Hepatology
🚨 New website update!
The AlcHepNet website now has a refreshed design and expanded content. Learn more about our ongoing clinical trial and the investigators advancing alcohol-associated hepatitis research.
Take a look 👇
https://t.co/25a6RnUNdj
#ITAALD#ClinicalTrials
New in @Hepatology: In >218K U.S. patients, AUD pharmacotherapy was linked to fewer hospitalizations and lower alcohol-related costs —greatest savings in advanced liver disease.https://t.co/SsuBPBzU6A
First post + big milestone! 🎉
The ITAALD Trial has officially enrolled its first patient in January. Huge thanks to our investigators and site teams for making this happen.
We’re just getting started. #ITAALD#ClinicalTrials